ATYR PHARMA INC

ATYRNASDAQ

🏆 #4682 by market capEarnings Nov 4US Equity

$0.31▲ $0.01 (+4.30%)

After hours · at close

🔔

Track ATYR

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 4.3%

7d▼ 13.3%

14d▼ 20.0%

30d▼ 42.5%

ytd▼ 60.3%

1y▼ 60.6%

🏦Market Cap

$30M

Small Cap

📈Revenue Growth (YoY)

-19.1%

Declining

📊Gross Margin

-11754.7%

Thin

💵FCF Margin

-28852.1%

Thin

⚖️P/S Ratio

153.7x

Expensive

Otter Score

Fair

Trading Snapshot

Day Range: $0.31 – $0.31
52-Week Range: $0.27 – $1.12
Volume: $3.55B
Avg Volume: $2.93B
Shares Outstanding: 98.1M
Next Earnings: Nov 30, 2026

Fundamentals Snapshot

Annual Revenue: $190,000
Last Q Revenue: $46,889
P/E Ratio: -0.5
P/S Ratio: 153.7x
EPS (TTM): $-0.62
Dividend Yield: 0.00%
Dilution (1yr): +18.5%

Why Investors Own ATYR

✓High-growth profile — revenue up +38.6% YoY with expanding US Equity exposure.
✓Healthy economics — 65% gross margin and 9% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ATYR PHARMA INC

ATYR

Financial Trends

Revenue

$190K▼ −19.1% YoY

Gross Margin

-717.4%▼ −817.4% YoY

Operating Income

−$78M▲ +14.3% YoY

Free Cash Flow

−$62M▼ −10.3% YoY

Shares Outstanding

98.0M▲ +18.5% YoY

Net Cash

−$1M▲ +$938K YoY

StockOtter · stockotter.space

About ATYR PHARMA INC

aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.

🦦